U.S. markets close in 50 minutes
  • S&P 500

    4,418.93
    +7.14 (+0.16%)
     
  • Dow 30

    35,122.53
    +60.98 (+0.17%)
     
  • Nasdaq

    14,835.81
    -1.19 (-0.01%)
     
  • Russell 2000

    2,213.60
    +3.95 (+0.18%)
     
  • Crude Oil

    72.18
    +0.11 (+0.15%)
     
  • Gold

    1,796.70
    -5.10 (-0.28%)
     
  • Silver

    25.25
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1806
    +0.0036 (+0.31%)
     
  • 10-Yr Bond

    1.2780
    -0.0080 (-0.62%)
     
  • GBP/USD

    1.3816
    +0.0062 (+0.45%)
     
  • USD/JPY

    110.3760
    -0.1340 (-0.12%)
     
  • BTC-USD

    39,886.28
    +5,564.19 (+16.21%)
     
  • CMC Crypto 200

    946.77
    +31.28 (+3.42%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Hemispherx, Bioclones to collaborate on HIV/AIDS eradication

Hemispherx Biopharma announced execution of an agreement to seek South African government approval to initiate a study of Alferon N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration. The study is contemplated as part of a broad strategic alliance with Bioclones, a South African biotechnology company. At the Wistar Institute, University of Pennsylvania, a recent clinical study was conducted to test the effect of Interferon Alfa-2a in the suppression and/or eradication of HIV. This pilot study yielded an exciting conclusion: alpha interferon resulted in control of HIV replication in 45% of patients following cessation of anti-retroviral therapy. Decreased levels of latent HIV occurred in patients in which HIV replication was suppressed by anti-retroviral drugs, supporting a role for immune-mediated approaches in HIV suppression and potential eradication of latent virus required for cure. Hemispherx' flagship products, Alferon N and Ampligen are both potentially key players in successful long-term immune-mediated therapy.